Elizabeth A. Eisenhauer
Queen's University · 264 works · 62,802 citations · h-index 73
Top works
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
- Individual patient data analysis to assess modifications to the RECIST criteria
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
- New guidelines to evaluate the response to treatment in solid tumors
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
- Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
- Health-related quality of life in patients with glioblastoma: a randomised controlled trial
- Progression-Free Survival: Meaningful or Simply Measurable?
- Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?
- Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
- Phase I Clinical Trial Design in Cancer Drug Development